Currently, the focus is only on the expression of PD-L1 on tumor cells; however, there is growing evidence that it should be extended to include immune cells, as well to generate a combined positive score (CPS), which can identify additional subgroups with treatment benefit [91]. The gene discussed is CD274; the disease is neoplasm.